News

BioSpace13h
‘Unprecedented’ FDA Leaks Sow Confusion For Patients, Sarepta and Capricor
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Zacks Investment Research on MSN2h
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...
MyChesCo on MSN23h
FDA Clears Path for Resumed Use of Elevidys Gene Therapy in Ambulatory DMD Patients
The U.S. Food and Drug Administration (FDA) has recommended lifting the voluntary clinical hold on Elevidys for ambulatory patients with Duchenne Muscular Dystrophy (DMD), following a thorough ...
Science-Based Medicine10h
EBM “Boy Wonder” Vinay Prasad is toppled
Evidence-based medicine "Boy Wonder" Dr. Vinay Prasad was fired as CBER Director after less than three months on the job.